To systematically assess clinical efficacy of Ligustrazine treating Idiopathic Pulmonary Fibrosis.Methods:Randomized controlled trials of Ligustrazine treating Idiopathic Pulmonary Fibrosis were selected with the deadline for March 2015.The researchers extract information according to inclusion and exclusion criteria and the risk of bias of included trials was assessed according to criteria recommended by Cochrane handbook for systematic reviews of interventions.Statistical analyses were performed by Review Manager 5.3 software.Results:7 qualified trials involving 388 participants were included.Metaanalysis indicated that Ligustrazine can improve treatment rate（RR=1.22，95%CI［1.08，1.39］)and level of PaO2(MD=6.20，95%CI［0.45，11.95］).Conclusion:Current evidence indicates that Ligustrazine may have certain curative effects in treating IPF，but security is not yet clear，however，we still need a large sample，multicenter，high quality clinical RCT.